Literature DB >> 10440465

Detection of the novel metabolite ethylphenidate after methylphenidate overdose with alcohol coingestion.

J S Markowitz1, B K Logan, F Diamond, K S Patrick.   

Abstract

Methylphenidate is the most commonly prescribed psychostimulant in clinical use today. Known methylphenidate metabolites include ritalinic acid, corresponding lactams, and p-hydroxymethylphenidate. Recent in vitro work using rat liver preparations has indicated that the methylphenidate ethyl ester, ethylphenidate, is formed upon incubation with ethanol. This report describes the first detection of ethylphenidate in human blood and liver samples obtained from two suicide victims who had overdosed on methylphenidate and coingested ethanol. Amounts of ethylphenidate detected in whole blood specimens in these two cases (8 ng/mL and 1 ng/mL, respectively) were small relative to methylphenidate and ritalinic acid concentrations. Nonetheless, given the high likelihood that methylphenidate and ethanol coingestion frequently occurs, the detection of ethylphenidate in humans warrants further investigation into the extent of its formation as well as into any associated toxicity in nonoverdose situations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10440465     DOI: 10.1097/00004714-199908000-00013

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  21 in total

Review 1.  Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects.

Authors:  Ricardo Jorge Dinis-Oliveira
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

Review 2.  Neuropsychiatric effects of prescription drug abuse.

Authors:  Jason P Caplan; Lucy A Epstein; Davin K Quinn; Jonathan R Stevens; Theodore A Stern
Journal:  Neuropsychol Rev       Date:  2007-08-16       Impact factor: 7.444

3.  Extended release stimulant medication misuse with alcohol co-administration.

Authors:  Jessica R Meisner; Christine Darredeau; Megan E McLarnon; Sean P Barrett
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2008-11

Review 4.  Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).

Authors:  Lingtak-Neander Chan; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

5.  Oral and transdermal DL-methylphenidate-ethanol interactions in C57BL/6J mice: potentiation of locomotor activity with oral delivery.

Authors:  Guinevere H Bell; William C Griffin; Kennerly S Patrick
Journal:  Pharmacol Biochem Behav       Date:  2011-09-08       Impact factor: 3.533

6.  Simultaneous use of non-medical ADHD prescription stimulants and alcohol among undergraduate students.

Authors:  Kathleen L Egan; Beth A Reboussin; Jill N Blocker; Mark Wolfson; Erin L Sutfin
Journal:  Drug Alcohol Depend       Date:  2012-12-28       Impact factor: 4.492

7.  Simultaneous co-ingestion of prescription stimulants, alcohol and other drugs: a multi-cohort national study of US adolescents.

Authors:  Sean Esteban McCabe; Brady T West; Ty S Schepis; Christian J Teter
Journal:  Hum Psychopharmacol       Date:  2014-11-05       Impact factor: 1.672

8.  Enantiospecific determination of DL-methylphenidate and DL-ethylphenidate in plasma by liquid chromatography-tandem mass spectrometry: application to human ethanol interactions.

Authors:  Hao-Jie Zhu; Kennerly S Patrick; John S Markowitz
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-02-25       Impact factor: 3.205

9.  Differential influences of ethanol on early exposure to racemic methylphenidate compared with dexmethylphenidate in humans.

Authors:  Kennerly S Patrick; Arthur B Straughn; Owen T Reeves; Hilary Bernstein; Guinevere H Bell; Erica R Anderson; Robert J Malcolm
Journal:  Drug Metab Dispos       Date:  2012-10-25       Impact factor: 3.922

10.  Methylphenidate Abuse and Psychiatric Side Effects.

Authors:  W Alexander Morton; Gwendolyn G. Stockton
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2000-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.